Today is the final trading session of the February F&O series for the Nifty contracts. The index has had a decent series so far
Author: admin
Analysis: Indonesia’s high-stakes trade bet with Washington nears its moment of truth
Uncertainty continues to surround Indonesia’s latest trade breakthrough as President Prabowo Subianto and United States President Donald Trump prepare to formalize the Agreement on
Stock Market LIVE Updates: GIFT Nifty down; Asian markets trade mixed; BS Manthan kicks off today
South Korea’s Kospi slipped 1.1 per cent, reversing early session gains. Australia’s S&P/ASX 200 also erased earlier advances to fall 0.1 per cent, while
Could investing $10,000 in IonQ make you a millionaire?
IonQ is one of the most popular quantum computing stocks.
Stock market today: Dow drops 800 points as S&P 500, Nasdaq slide on Trump tariff fears, AI ‘scare trade’
Wall Street has been buffeted by the winds of Trump’s tariffs over the weekend. A SCOTUS ruling was quickly refuted by the president in
Here’s Why Oracle Stock Slumped Today
Investors continue to fret whether the company has bitten off more than it can chew with its AI-spending commitments.
Dow Jones free fall today: Why is the Dow Jones falling so sharply – Dow, S&P 500 and Nasdaq plunge deep into the red
Dow Jones in free fall today. The Dow plunged 689 points to 48,936, down 1.39%. The S&P 500 fell 0.67% to 6,863. The Nasdaq
Stock futures are little changed after major indexes sell off on anxiety over AI disruption, tariffs: Live updates
Investors are awaiting consumer confidence data and Home Depot earnings out Tuesday. They’re also bracing for key earnings results from Nvidia later this week.
Stock Market Today, Feb. 23: SoFi Technologies Pulls Back as Investors Reassess Fintech Momentum
SoFi shares pulled back during a broader fintech selloff, even as the company continues to scale revenue and profitability. Investors are taking a closer
Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short
Today, Feb. 23, 2026, a pivotal obesity‑drug trial setback forces investors to rethink Novo Nordisk’s strategy.